Tag: initial

Categories
World News

High shareholder Data Edge on the preliminary public providing

Top shareholder Info Edge on the initial public offering

A Zomato Delivery boy adjusts a grocery order in his delivery bike amid the Covid-19 (Coronavirus) pandemic on November 8, 2020 in New Delhi, India.

Nasir Kachroo | NurPhoto | Getty Images

Indian internet company Info Edge has no plans to sell its entire stake in Zomato if the grocery delivery startup goes public, a senior executive said.

Zomato filed for an initial public offering of up to Rs. 82.5 billion ($ 1.1 billion) in April, in which the company will issue new shares valued at up to Rs. 75 billion. The company plans to use the proceeds to fund organic and inorganic growth initiatives, which may include mergers or acquisitions.

Info Edge, the startup’s largest shareholder, will sell shares valued at up to 7.5 billion rupees ($ 101 million), the company said in an IPO in April.

“We continue to invest in Zomato, we will not sell our entire stake,” said Chintan Thakkar, CFO and Executive Director at Info Edge, told CNBC’s Street Signs Asia on Tuesday.

Zomato participants

Info Edge was the first institutional investor to support Zomato and, according to Thakkar, currently holds around 17% of the shares in the start-up. Other shareholders include rideshare giant Uber, Alibaba subsidiary Ant Group and Singapore state investor Temasek.

“What we announced is that we could hit up to $ 100 million,” he said, referring to the number of Zomato shares Info Edge could sell. “We still have the option of not paying even $ 100 million.”

“Most of our stake will likely stay in Zomato, so we will keep investing in it,” said Thakkar.

Thakkar didn’t want to reveal when Zomato’s IPO could take place.

He said anything Info Edge receives from the offering will be added to existing funds that are likely to be used in the company’s operations and can be used to buy or acquire a strategic minority stake in potential midsize companies.

Info Edge will primarily deal with technology startups or “anything that has a sizeable market and can disrupt the existing market,” he added.

India’s fragmented food delivery scene

Together with rival start-up Swiggy, Zomato dominates the US $ 4.2 billion grocery delivery market in India, which is highly competitive but also very fragmented.

In its prospectus, Zomato said it faces intense competition from chain restaurants that have their own online ordering platforms. Other competitors are cloud kitchens and restaurants that operate their own delivery fleets, as well as offline orders over the phone.

The company also said the pandemic had a significant impact on business last year as most restaurants were temporarily closed and many customers were unwilling to order outside food. Zomato said its restaurant service income was also severely impacted.

In February, Zomato said it raised $ 250 million from donors like Tiger Global Management and Fidelity. That was months after a $ 660 million financing round closed.

Categories
Health

Detroit mayor rejects preliminary J&J vaccine cargo, calls Pfizer, Moderna ‘the very best’

Detroit mayor rejects initial J&J vaccine shipment, calls Pfizer, Moderna 'the best'

Vial of the Janssen Coronavirus Disease (COVID-19) vaccine from Johnson & Johnson

Johnson & Johnson via Reuters

Detroit Mayor Mike Duggan turned down an initial allocation of the Johnson & Johnson Covid-19 single vaccine this week, according to the Michigan State Department of Health.

At a news conference Thursday, Duggan confirmed that he had refused to grant J&J vaccines from the state this week, citing sufficient supply of Pfizer and Moderna vaccines to meet demand from eligible residents.

“Johnson & Johnson is a very good vaccine. Moderna and Pfizer are the best. And I’ll do everything I can to make sure the Detroit city residents get the best,” Duggan said at a news conference Thursday.

The FDA on Saturday approved J & J’s Covid-19 vaccine for emergency use. This makes it the third vaccine approved for distribution in the United States and the only vaccine that requires only one dose.

Clinical trial data shows that J & J’s vaccine provides 66% overall protection against Covid, compared to around 95% for Pfizer and Moderna vaccines. While some have raised concerns about the J&J vaccine’s lower rate of effectiveness, the J&J vaccine has been shown to prevent 100% of virus-related hospitalizations and deaths, according to clinical trial data.

“All vaccines are safe and effective, and I recommend that all vaccines be offered in all communities,” said Dr. Michigan chief medical executive Joneigh Khaldun in a statement to CNBC.

“Also, the Johnson and Johnson vaccine has been studied in a more recent period of time with more easily transmissible variants, so I would not recommend comparing the Pfizer and Moderna studies directly with the Johnson and Johnson studies,” Khaldun said.

At a news conference on Friday, Andy Slavitt, Senior White House Covid Advisor, said Duggan’s comments on the J&J vaccine had been misunderstood.

“We have had a constant dialogue with Mayor Duggan … He is very excited about the Johnson & Johnson vaccine. And I think we want to reiterate the message that the very first vaccine we can take makes perfect sense for all of us is take, “said Slavitt.

In a statement later Friday, Duggan reiterated the effectiveness of the J&J shot in preventing hospitalizations and Covid-related deaths.

“The only reason we decided not to take the first shipment from Johnson & Johnson was because we had the capacity with Moderna and Pfizer to handle the 29,000 first and second dose appointments planned for the coming week which has already brought us very close to our capacity at our current locations, “Duggan said in a statement on Friday.

The J&J allotment, rejected by Duggan, comprised 6,200 doses that were distributed to other local Michigan health departments, according to Bob Wheaton, spokesman for the state health department.

Wheaton said the state doesn’t expect to receive any more J&J vaccines “for a few weeks.”

Duggan said the city will open a new vaccination site for J&J shots if demand from eligible residents exceeds supply of Moderna and Pfizer cans.

“We always planned to distribute Johnson & Johnson as soon as demand warranted it, and we had our distribution plan so we could make it available to our residents as much as Moderna and Pfizer,” Duggan said in Friday’s statement. “By the time the next J&J broadcast arrives, we’ll have our plan to make it available.”

Categories
Health

Moderna seems to be to check Covid-19 booster photographs a yr after preliminary vaccination

Moderna looks to test Covid-19 booster shots a year after initial vaccination

One of the boxes containing the Moderna COVID-19 vaccine is prepared for shipment at the McKesson distribution center in Olive Branch, Mississippi, USA, on December 20, 2020.

Paul Sancya | Reuters

Moderna plans to test a booster shot of its Covid-19 vaccine a year after the first two-dose immunization, as the duration of protection from the new vaccines is still unclear.

The biotech company plans to start the study in July. This emerges from a company presentation at the JPMorgan Healthcare Conference on Monday. According to an email shared by one of those people, employees at the clinical trial sites have already started contacting participants in previous trials.

“From what we’ve seen so far, we’re assuming the vaccination will take at least a year,” said Dr. Tal Zaks, Moderna’s Chief Medical Officer, told investors and analysts at the conference. “To the extent that you need a booster shot, we make a data-based recommendation, and for that we need to pull the data.”

The first participants in Moderna’s human clinical trials received their recordings in mid-March. a second was given four weeks later. Since multiple doses of the vaccine were tested in previous studies, those with doses lower than the ultimately approved – 100 micrograms – would get their booster sooner, while those with 100 micrograms or higher would get their booster at the end of the year, according to an email to the Attendees.

The booster that is now planned is the same version of the vaccine that is on the market, but Stephane Bancel, CEO of Moderna, said it might be necessary to adapt the vaccine in the coming years to cover new variants.

“I think this is going to be a market like the flu,” he told CNBC. Moderna also recently started a seasonal flu vaccination program.

The booster study for Moderna’s Covid-19 vaccine will assess both safety and the immune response that an additional shot generates a year later, Bancel said at the conference.